Retatrutide, an investigational once-weekly triple agonist from Eli Lilly, targets three metabolic pathways (GLP-1, GIP, and glucagon)
This is a conversation we have regularly at our Doral clinic
Are your liver enzymes slowly creeping up, or are they staying stable
Its prevalence increases significantly as renal function declines, affecting over 90% of dialysis patients
Calorie deficit support GLPer automatically calculates your Total Daily Energy Expenditure (TDEE) and adjusts as your bodyweight changes
And the herbal wellness category continues to attract consumer interest, including products marketed using terms like "GLP-1 patch." If you are considering these options, here are some important things to keep in mind, no matter what you choose: Talk to your healthcare provider